Patent intelligence · US
US 12138247
Non-sedating dexmedetomidine treatment regimens
Non-sedating dexmedetomidine treatment regimens
Patent details — US 12138247
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 12, 2024
- Expiration
- Nov 7, 2044
- Applicant
- BioXcel Therapeutics, Inc.
- Claims
- 6
- CPC classes
- A61K, A61K31/4174, A61K47/38, A61K9/006
Quick answer
US 12138247 (Non-sedating dexmedetomidine treatment regimens) is held by BioXcel Therapeutics, Inc.. Status: granted. Granted Nov 12, 2024. Expires Nov 7, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BioXcel Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K31/4174, A61K47/38, A61K9/006, A61P, A61P25/18
More from BioXcel Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12364683
Non-sedating dexmedetomidine treatment regimens
granted -
US 12109196
Non-sedating dexmedetomidine treatment regimens
granted -
US 12090140
Non-sedating dexmedetomidine treatment regimens
granted -
US 11998528
Non-sedating dexmedetomidine treatment regimens
granted -
US 11998529
Non-sedating dexmedetomidine treatment regimens
granted -
US 11931340
Use of sublingual dexmedetomidine for the treatment of agitation
granted -
US 11890272
Non-sedating dexmedetomidine treatment regimens
granted
Frequently asked questions
What is US patent 12138247?
US 12138247 (Non-sedating dexmedetomidine treatment regimens) is held by BioXcel Therapeutics, Inc.. Status: granted. Granted Nov 12, 2024. Expires Nov 7, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12138247?
BioXcel Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 18 pharmaceutical patents for this assignee.
When does US 12138247 expire?
Our index shows an expiration date of Nov 7, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.